NewAmsterdam Pharma Co N.V.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
NAMS$19.00+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30,2025 | December 31,2024 | |
|---|---|---|
| (In thousands of USD) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 538,407 | 771,743 |
| Prepayments and other receivables | 28,074 | 24,272 |
| Employee receivables | — | 4,951 |
| Marketable securities, current | 164,539 | 62,447 |
| Restricted cash | 1,308 | — |
| Total current assets | 732,328 | 863,413 |
| Marketable securities, net of current portion | 53,091 | — |
| Property, plant and equipment, net | 323 | 242 |
| Operating right of use asset | 246 | 431 |
| Intangible assets | 439 | 534 |
| Total assets | 786,427 | 864,620 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 3,632 | 4,744 |
| Accrued expenses and other current liabilities | 10,098 | 13,608 |
| Deferred revenue, current | — | 6,008 |
| Lease liability, current | 181 | 246 |
| Derivative earnout liability, current | — | 44,798 |
| Derivative warrant liabilities | 44,361 | 37,514 |
| Total current liabilities | 58,272 | 106,918 |
| Lease liability, net of current portion | 85 | 202 |
| Total liabilities | 58,357 | 107,120 |
| Commitments and contingencies (Note 12) | ||
| Shareholders' Equity (deficit): | ||
| Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 113,172,684 and 108,064,340 shares issued and outstanding as at September 30, 2025 and December 31, 2024, respectively | 14,107 | 13,444 |
| Additional paid-in capital | 1,396,790 | 1,298,160 |
| Accumulated loss | (687,467) | (558,571) |
| Accumulated other comprehensive income | 4,640 | 4,467 |
| Total shareholders' equity | 728,070 | 757,500 |
| Total liabilities and shareholders' equity | 786,427 | 864,620 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.